Breaking
FDA crackdown on Cipla Pharma's Pune unit,license cancelled over 'unauthorised promotional text'
The FDA seized Reactin Plus stock worth ₹11.19 lakh and ordered the firm to recall the drug from the market.
This story summarizes reporting from Hindustan Times. Read the original for full context. Wire items stay in our news sitemap for seven days. Editorial policy.
Read full story on Hindustan Times →
India — Hindustan Times

